Compare Natera Inc. Common Stock (NTRA) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard International High Dividend Yield ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Vanguard International High Dividend Yield ETF trades at $100.51 (market cap $22.80B). The key difference: Natera Inc. Common Stock is far larger — about 2.5× Vanguard International High Dividend Yield ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard International High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard International High Dividend Yield ETF for 51 Days on average.
| NTRA | VYMI | |
|---|---|---|
Market Cap | $57.03B | $22.80B |
Volume | 1,131,157 | 740,346 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $107.13 |
52-Week Low | $179.42 | $84.45 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VYMI trades at $101.52, up 0.71% with a bearish technical signal from moving averages. The ETF shows strong institutional interest with Envestnet increasing holdings by 22% in Q2 2026. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with a 5-year average annual return of 14.13% according to Seeking Alpha on September 21, 2026.
The outlook remains positive with sector catalysts in financials, energy, and healthcare supporting dividend growth. Key risks include global market volatility and currency exposure. Analyst sentiment leans bullish with VYMI positioned as an attractive international dividend play amid rising global rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
